LEADING ARTICLE

Management of Hypertension in the Elderly and Frail Patient

Luigina Guasti1 · Marco Ambrosetti2 · Marco Ferrari1,3 · Franca Marino1,3 · Marc Ferrini4 · Isabella Sudano5 · Maria Laura Tanda1 · Iris Parrini6 · Riccardo Asteggiiano1,7 · Marco Cosentino1,3

Accepted: 7 July 2022 / Published online: 29 July 2022 © The Author(s) 2022, corrected publication 2022

Abstract
Hypertension is a frequent finding in elderly patients. Hypertension in older age can be both associated with frailty and represent a risk factor for frailty. Hypertension is recognized as a main risk factor for cardiovascular diseases such as heart failure, atrial fibrillation, and stroke and the occurrence of these diseases may provoke a decline in health status and/or worsen the degree of frailty. Blood pressure targets in hypertensive older and frail patients are not completely defined. However, specific evaluations of individual patients and their co-morbidities and assessment of domains and components of frailty, together with weighted consideration of drug use, may help in finding the appropriate therapy.

Key Points
Frailty and hypertension are frequently found in the elderly and are closely interconnected.

A personalized approach is needed in the management of hypertension in older persons, focusing on hypotension, comorbidities, and adherence/persistence to medical prescriptions, while considering the specific frailty deficits.

Pharmacogenetics might help in identifying (and preventing) frailty statuses associated with pharmacological treatments.

1 Frailty
The definition of frailty includes various aspects of patient evaluation and tends to capture the subject of vulnerability or the global risk of patients’ inability to withstand potential acute stressors [1–5]. The classical domains that have been identified are the physical domain, the medical domain, the cognitive/depressive domain, and the social domain [6, 7]. Various deficits may combine to confer a frailty status to the patient.

For instance, among the medical domains, deficits could be related to multi-morbidity, polypharmacy, and nutrition, and these could be associated with deficits in other domains, thus increasing the degree of frailty (Fig. 1).

Although frailty is closely related with ageing and multi-morbidity, some components of frailty may change over time and even improve [8]. For instance, a patient could be particularly frail after an acute traumatic or ischemic vascular event, with the deleterious effects of hospitalization in older patients and the need for multidrug therapy. However, the same patient after some weeks of support focused on the main deficits evidenced by the subject may have improved health status and be completely recovered, thus returning to the same level of frailty as before the event (Fig. 2).

Traditionally the two models to approach frailty are the phenotype model and the cumulative deficit approach [9–12], identifying also minor degrees of frailty called pre-frailty. Moreover, the comprehensive geriatric assessment or multidimensional approaches are more representative of global complexity assessment, though time consuming [13–16]. Short multidimensional approaches such as the
Essential Frailty Toolset have been shown to have an additive predictive value in specific cardiovascular diseases such as aortic stenosis or cardiac surgery [17, 18] and are becoming popular, particularly in the general cardiology ambulatory setting, due to their feasibility.

## 2 Frailty in Cardiology

Increasing evidence points to a role of the immune system and inflammation in the atherosclerosis process, together with the classical risk factors including ageing, low-density lipoprotein cholesterol, hypertension, smoking habits, and diabetes mellitus [19]. The cellular and vascular changes are characterized by functional and morphological alterations of circulating immune cells and endothelial cells occurring early in the atherosclerosis development, and by obstructive lesions which may lead to downstream tissue ischemia and necrosis [19–21]. Frailty often begins with recognized changes at molecular, cellular, and system levels with physiological impairment due to inflammation, sarcopenia and osteopenia, and neuroendocrine dysregulation [22, 23]. A shared pathophysiology between cardiovascular diseases risk and frailty has been suggested and both frailty and pre-frailty constitute independent risk factors for cardiovascular diseases and for cardiovascular mortality in older adults [24, 25]. Both cross-sectional and longitudinal findings show that frailty is closely related with cardiovascular diseases [25, 26]. In particular, frailty is more prevalent in patients with peripheral artery disease and heart failure whereas mainly heart failure was associated with incident frailty over time [26]. The identification of deficits and a screening for frailty provide the chance to highlight the potentially modifiable components of frailty, and, when identified, to provide a better definition of patient risk [7]. General support and management of frailty includes nutrition, exercise, and cognitive/emotional support, a multicomponent rehabilitation program when needed, focus on environmental aspects to reduce falls, a guarantee of social support, and targeting of inappropriate polypharmacy, while not denying appropriate treatments and reducing hospitalization periods when needed [7, 27]. Nutritional support before scheduled cardiac surgery has been suggested as a strategy to prevent frailty [28].

### 3 Hypertension and Frailty

The relationship between frailty and hypertension is difficult to interpret because hypertension could represent both a risk factor for the development of frailty [29] and a coexisting condition. In the cumulative deficit approach, which together with the Fried phenotype model constitutes the commonly used method for detecting frailty [9–11], hypertension is included in the accumulation of diagnoses and leads to a higher frailty score. The prevalence of hypertension is up to 80% in patients with frailty and appears to be significantly associated with lower cognitive performance and sedentary habits [30].

Patients with frailty may present with both low and high blood pressure (BP) values, with a typical U-shaped relationship [31, 32]. In a sub-study of the Systolic Blood Pressure Intervention Trial (SPRINT) [33], the state of frailty was characterized by the intake of a greater number of anti-hypertensive drugs. Other series showed lower BP values in frail patients with increased presence of comorbidities, malnutrition, and overtreatment [34, 35]. Frailty was associated with higher risk of non-dipping and reduced night-time systolic BP fall in a small study evaluating 24-h ambulatory BP, possibly indicating an effect of frailty on sleep quality and mobility, vascular endothelial dysfunction or impairment in the autonomic system [36]. However, differences in the BP pattern may simply reflect a selection bias of evaluated patients.
patient populations; in particular, low BP would appear in the context of severely frail patients as a marker of reduced functional reserve and poor baseline health [37].

There is still insufficient evidence to establish a BP target in the elderly [38]; this population, especially patients with frailty, are often excluded from trials or are without precise identification in most studies, and thus suffer from the lack of recommendations. When participants of the SPRING trial were characterized according to frailty measures, the patients were found to have a similar degree of frailty compared with other large trials with ambulatory patients [33]. However, particular subgroups of frail older persons underrepresented in clinical research are those who are institutionalized, requiring nursing, or with dementia, with a marked ‘gap in evidence’. In addition, most large trials on hypertension in older persons exclude patients with orthostatic hypotension, which is one major concern in treating older persons and the different domains and components of frailty are not disentangled, even in studies reporting frailty status. Moreover, in published literature, different age ranges are considered when studies on older persons are focussed on, making it difficult to compare results. Major guidelines suggest “individualized BP target” [39], “clinical judgement” [40], “determination of tolerance” [41], or “caution for intensive BP lowering” [42] without providing an indication as to what extent BP-lowering treatment benefits this patient population. This is probably due to accumulating evidence from several observational studies on neutral or adverse effects on mortality by targeting low BP values. The review by Todd et al. [43]—albeit limited by wide heterogeneity in frailty measures among considered studies—showed that in patients with frailty there was no difference in all-cause mortality between systolic BP < 140 mmHg and ≥ 140 mmHg. In a large administrative database from the United Kingdom [44], an excess of all-cause mortality was recently found in patients with frailty who showed a systolic BP < 130 mmHg, without significant reduction in cardiovascular risk. This negative effect of low BP on mortality seems to be mostly related to those receiving antihypertensive drugs as compared with those presenting with spontaneous low BP [45]. In the HYpertension in the Very Elderly Trial (HYVET), targeting a BP of 150/80 mmHg in adults aged 80 years or older was associated with lower mortality also after adjustment for baseline frailty, with a 36% risk reduction of stroke and a 41% risk reduction of fatal and nonfatal cardiovascular events [46]. However, the prognostic role of BP on mortality and cardiovascular prognosis is probably not uniquely related to age, being better described by non-chronological variables such as ‘vascular ageing’, the global functional capacity, and cognitive performance [47].

For these reasons, managing hypertension in frail patients cannot be reduced to a treat-to-target approach to improve cardiovascular prognosis, and needs to be integrated with an individualized risk/benefit evaluation. This latter should include the comparison between the time-until-benefit of antihypertensive treatment and individual life expectancy, which often constitutes a missed estimation in most patients. Second, changes in pharmacokinetics induced by advanced age and the risk of drug–drug interactions should be taken into consideration with respect to the increased vulnerability to hypotension-related adverse events and a move towards deprescribing in selected cases.

4 Hypertension Drug Treatment and Frailty

4.1 Pharmacological Therapy of Hypertension

Pharmacological treatment of hypertension first of all includes agents such as diuretics (thiazide and thiazide-like diuretics), angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) and dihydropyridine calcium channel blockers (CCBs), alone or in combination. β-Blockers should be considered in the presence of cardiac conditions such as ischemic heart disease, atrial fibrillation or heart failure. Finally, current guidelines suggest the administration of triple-drug combinations, if the target BP is still unattained [39, 48].

Despite good efficacy and low frequency of side effects associated with antihypertensive therapy, achievement of adequate BP control is reported in only about half of treated patients [49–51].

4.2 Pharmacological Therapy of Hypertension in Frail Subjects

The relationship between frailty and hypertension includes two fundamental aspects. First of all, antihypertensive treatment may represent a risk factor for the development of frailty, in particular when double- or triple-drug combinations are employed [52–54]. On the other hand, frailty itself may increase the risk of treatment failure as well as of drug-induced side effects which, in a negative loop, result in increased patient frailty [55]. Moreover, specific adverse effects which need specific precautions may be associated with antihypertensive drugs in individuals aged 80+ years (for details see Table 3 of Benetos et al. 2019 [56]). Thus, an individualized approach is the best choice for the treatment of hypertension in patients with frailty. Nevertheless, older (and frailer) hypertensive patients have been shown to benefit from antihypertensive therapy [53, 57], as indicated by two large, randomized studies which included elderly and frail patients with a frailty distribution similar to that in the outpatient population. In these studies, antihypertensive treatment reduced coronary artery disease risk, heart failure,
stroke, and other causes of mortality in older patients, even in frail ones [58, 59].

However, as already mentioned above, antihypertensive treatment presents certain risks in frail older adults. In the SPRINT study, frail older adults receiving intensive antihypertensive treatment showed an increased risk of hypotension, syncope, electrolyte imbalance, and acute kidney injury [60]. Moreover, since participants included in the aforementioned studies were relatively robust and had a lower rate of comorbidity [46, 61], the assessment of the degree of frailty has been recommended before starting antihypertensive treatment in frail older adults [59].

The main risk associated with antihypertensive treatment in frail older adult patients is overtreatment [35], and observational studies on hypertension in the older population suggest that aggressive BP lowering may be one of the main causes of worsening of frail patients’ conditions [52–54]. For this reason, current guidelines for hypertension recommend older hypertensive patients with frailty to be initially treated with monotherapy [61, 62]. Moreover, when systolic BP drops to or below 140 mmHg, antihypertensive administration should be reduced as much as possible, except in limited and special circumstances. Finally, no more than two antihypertensive drugs should be prescribed [63]. Concerning the choice of antihypertensive drugs in frail patients, no definitive evidence exists in frail patients supporting one class of antihypertensive drugs as safer compared with others. However, CCBs have been hypothesized to have a protective effect in frail older hypertensive patients [64] and ACEIs may prevent frailty by increasing muscle mass in lower limbs and muscle strength [65, 66].

4.3 Pharmacogenetics and Frailty in Antihypertensive Drug Therapy

The observation of a familial component in drug action opened the way to the idea of pharmacogenetics (PGx), defined as the study of inter-individual variations in DNA sequences related to drug response (EMEA/CPMP/3070/01: Position paper on terminology in Pharmacogenetics) [107]. The goal of PGx is to associate a patient’s genetic profile with his/her response to treatment, thus determining drug efficacy and toxicity before therapy initiation. This ‘precision medicine’ approach could allow a safer and more effective use of pharmacotherapy [67] and, in turn, reduce the patients’ frailty condition.

Differences in patients’ genetic profile are due to the presence of genetic polymorphisms which include insertion/deletion, copy number variations, mini- and micro-satellites, and single nucleotide polymorphisms (SNPs, i.e. DNA sequence variations occurring when a single nucleotide in the genome differs between paired chromosomes). SNPs are the most common type of genetic variations among people, and are responsible alone for 90% of all genetic differences between individuals [68].

Genome-wide association studies (GWASs) led to the discovery of several genetic variants associated with both antihypertensive drug efficacy as well as drug-induced side effects [69, 70]. In Table 1 we summarize the most common polymorphisms in genes affecting antihypertensive drug response (for further details, see Rysz et al. 2020 [71]).

So far, there is no evidence for a direct relationship between subjects’ genetic profile and frailty status in patients treated with antihypertensive drugs. However, patient’s genotype has been suggested to contribute, together with other conditions (age, polypharmacy, co-morbidity, etc.), to frailty status in hypertensive patients in different ways by engaging in the pathophysiology of hypertension development, and by altering drug effects through modification of pharmacodynamic interactions between drugs and their targets. Moreover, drug responses might be affected by genetic polymorphisms both in genes encoding for drug-metabolizing enzymes/transporters or in pleiotropic genes participating in metabolic reactions and complex cascades [72, 73]. In any case, the relative role of specific genes and polymorphisms in frail subjects has been hypothesized to differ from non-frail people in terms of both therapy efficacy and drug-induced side effects.

For example, it is well known that falls cause a significant increase in morbidity and in turn in frailty status, especially in older persons [74]. Interestingly, older adults with uncontrolled hypertension (mainly due to drug therapy failure) and orthostatic systolic hypotension were shown to be at greater risk for falls than patients with good response to drug therapy [75]. Moreover, side effects induced by β-blockers (such as hypotension) were also associated with falls [76]. In the light of these results, it seems reasonable to assume that differences in patient’s genetic profiles could both increase each subject’s frailty state, in particular, when such state results from a therapy failure and/or side effects, and contribute to drug-induced side effects in patients with frailty compared with non-frail people.

In conclusion, the identification of genomic biomarkers for therapy outcome (i.e. effectiveness/ineffectiveness and drug-induced side effects) might help in identifying (and preventing) frailty statuses associated with pharmacological treatments.

5 Clinical Practice

When considering hypertension in older persons, our concern should focus on hypotension. Orthostatic hypotension affects the prognosis in older people not only by increasing the risk of syncope and falls, but also by increasing
Hypertension in the Elderly and Frail

CV risk and all-cause mortality [7, 93–96]. Therefore, our main goal when treating hypertension in the elderly is to carefully titrate antihypertensive therapy, also in standing position, which should form part of the standard evaluation in elderly and in patients with frailty [7]. The current ESC guidelines suggest specific recommendations for these patients, that is, to maintain a 130–140 mmHg systolic target and 80–90 mmHg diastolic target, if tolerated, and to consider monotherapy as a first-line strategy in older and frail patients [41]. However, clinical judgement, based on biological age, remains the first fundamental step in complex medical contexts, especially when treating older persons with frailty [97].

Specific considerations should be made in patients with comorbidities such as atrial fibrillation [98]. A high prevalence of left ventricular hypertrophy was found in patients with non-valvular atrial fibrillation, associated with older age, hypertension, and other factors such as female gender, diabetes, and previous myocardial infarction [99]. The correct stratification of cerebrovascular risk for patients with non-valvular atrial fibrillation requires the recognition of left ventricular hypertrophy [100]. Hypo- and hyper-thyroidism, including subclinical hyperthyroidism, are frequent diseases in elderly patients which are able to interfere with both BP values, antihypertensive treatments and cardiovascular health [101, 102]. Moreover, other conditions potentially worsening during hypotension, such as myocardial ischemia, stroke, worsening of hypotension in aortic stenosis, hypotension during meals, should be considered when treating hypertension in the elderly.

Critical steps during treatment are adherence, persistence, and the correct understanding of medication

### Table 1

Selected gene polymorphisms affecting the clinical response to antihypertensive drugs

| Drug                     | Gene                  | Polymorphisms | Effects | References |
|--------------------------|-----------------------|---------------|---------|------------|
| Thiazides and thiazide-like diuretics | ACE                   | rs1799752     | ↑ response | [77]       |
| Hydrochlorothiazide      | ACE                   | rs1799752     | ↑ response | [78]       |
|                          | ADD1                  | rs4961        | ↑ response | [79]       |
|                          | GNB3                  | rs5443        | ↑ response | [80]       |
|                          | NEDD4L                | rs4149601     | ↑ response | [81]       |
| ARBs                     | Losartan              | NPHS1         | rs3814995 | ↑ response | [82]       |
|                          | CAMK1D                | rs10752271    | ↑ response | [83]       |
| Candesartan              | SCNN1G                | rs11649420    | ↑ response | [84]       |
|                          | GPR83                 | rs3758785     | ↑ response | [84]       |
| ACEis                    | Enalapril             | NOS3          | rs3918226 | ↑ response | [85]       |
|                          |                      |               | rs3918188 | ↓ response | [85]       |
|                          |                      |               | rs2070744 | ↑ response | [86]       |
|                          | PRKCA                 | rs16960228    | ↑ response | [85]       |
|                          | BDKRB2                | rs1799722     | ↑ response | [86]       |
| DHP-CCBs                 | Verapamil             | KCNMB1        | rs1173916 | ↑ response | [87]       |
|                          |                      | CACNA1C       | rs1051375 | ↓ response | [88]       |
|                          |                      | CACNB2        | rs2357928 | ↑ side effects | [88]     |
|                          |                      | CYP3A5        | rs10264272| ↑ response  | [89]       |
| Amlodipine               | CYP3A4                | rs2740574     | ↑ response | [90]       |
|                          |                      |               | rs2246709 | ↑ response  | [90]       |
|                          | CYP3A5                | rs776746      | ↓ plasma conc. | [91]      |
|                          | ABCB1                 | rs1046542     | ↑ oral clearance | [92]     |

**ABC1** ATP Binding Cassette Subfamily B Member 1, **ACE** angiotensin-converting enzyme, **ACEis** ACE inhibitors, **ADD1** Adducin, **ARBs** angiotensin II receptor blockers, **BDKRB2** Bradykinin Receptor B2, **CACNA1C** Calcium Voltage-Gated Channel Subunit Alpha1 C, **CACNB2** Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2, **CAMK1D** Calcium/Calmodulin Dependent Protein Kinase, ID, **GNB3** G Protein Subunit Beta 3, **CYP3A5** Cytochrome P450 Family 3 Subfamily A Member 5, **CYP3A4** Cytochrome P450 Family 3 Subfamily A Member 4, **DHP-CCBs** dihydropyridine calcium channel blockers, **GPR83** G Protein-Coupled Receptor 83, **KCNMB1** Potassium Calcium-Activated Channel Subfamily M Regulatory Beta Subunit 1, **NEDD4L** Like E3 Ubiquitin Protein Ligase, **NOS3** Nitric Oxide Synthase 3, **NPHS1** Adhesion Molecule, Nephrin, **PRKCA** Protein Kinase C Alpha, **SCNN1G** Sodium Channel Epithelial 1 Subunit Gamma

△ Adis
schedules [103, 104]. These factors could limit the target achievement and/or influence potential adverse reactions to drugs in all hypertensive patients and particularly in the oldest ones. Shared decision making about a treatment plan includes initial acceptance and implementation, follow-up appointments, and adjustments in drug schedules [56]. Elderly patients with social frailty may be limited by difficulties measuring BP values, reaching the doctor’s office, and filling drug prescriptions. Moreover, cognitive frailty and/or medical frailty such as the condition that can occur in patients with post-stroke disabilities may limit the correct timing and understanding of drug schedules.

Finally, the use of digital health technologies is rapidly expanding in the evaluation of hypertension and cardiac diseases, and this support to clinical practice seems to be particularly useful in the older population to facilitate telemedicine, teleconsults, interactions with caregivers, and adherence to medical prescriptions [105, 106].

Declarations

Funding Open access funding provided by Università degli Studi dell’Insubria within the CRUI-CARE Agreement.

Conflict of interest Luigina Guasti, Marco Ambrosetti, Marco Ferrari, Franca Marino, Marc Ferrini, Isabella Sudano, Maria Laura Tanda, Iris Parrini, Riccardo Asteggiiano, and Marco Cosentino declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Ethics approval Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Availability of data Not applicable.

Code availability Not applicable.

Authors’ contributions LG gave the principal contribution to the manuscript. All the authors, LG, MA, MF, FM, IS, MLT, IP, RA, and MC contributed to the conceptualization, supervision, writing and reviewing of the manuscript.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumley WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarry RJ, Gutierrez-Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7.

2. Rodriguez-Mañas L, Féart C, Mann G, Viña J, Chatterji S, Chodzko-Zajko W, Gonzalez-Colaço Harmand M, Bergman H, Carcaillon L, Nicholson C, Scuteri A, Sinclair A, Pelaez M, Van der Cammen T, Beland F, Bickenbach J, Delamarche P, Ferrucci L, Fried LP, Gutiérrez-Robledo LM, Rockwood K, Rodríguez-Artalejo F, Serviddio G, Vega E, FOD-CC group. Searching for an operational definition of frailty: a Delphi method based consensus statement the frailty operative definition-consensus conference project. J Gerontol A Biol Sci Med Sci. 2013;68:62–7.

3. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59:255–63.

4. Clegg A, Young J, Iliffe S, Rikkest MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381:752–62.

5. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice and public health. Lancet. 2019;394:1365–75.

6. Gorodeski EZ, Goyal P, Hummel SL, Krishnaswami A, Goodlin SJ, Hart LL, Forman DE, Wenger NK, Kirkpatrick JN, Alexander KP, Geriatric Cardiology Section Leadership Council, American College of Cardiology. Domain management approach to heart failure in the geriatric patient: present and future. J Am Coll Cardiol. 2018;71:1921–36.

7. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, Savelieva I, Fumagalli S, Bo M, Rocca B, Jensen MT, Pierard L, Sudano I, Aboyans V, Asteggianno R. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol. 2022;29:216–27.

8. Kojima G, Taniguchi Y, Iliffe S, Jivraj S, Walters K. Transitions between frailty states among community-dwelling older people: a systematic review and meta-analysis. Ageing Res Rev. 2019;50:81–8.

9. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Grottiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.

10. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2002;57:M128–34.

11. Rockwood K, Mitnitski A, McInnes EM, Fortin M, Thiele RJ, Rockwood CM. Accumulating frailty risk factors in an older population: the impact of initial frailty status and time. J Gerontol A Biol Sci Med Sci. 2003;58:M385–90.

12. Cesari M, Franchi C, Cortesi L, Nobili A, Ardoino I, Mannucci PM, REPOSI collaborators. Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register. Eur J Intern Med. 2018;56:11–8.

△ Adis
13. Pilotto A, Addante F, Franceschi M, Leandro G, Rengo G, D’Ambrosio P, Longo MG, Rengo F, Pellegrini F, Dallapiccola B, Ferrucci L. Multidimensional Prognostic Index based on a comprehensive geriatric assessment predicts short-term mortality in older patients with heart failure. Circ Heart Fail. 2010;3:14–20.

14. Ellis G, Whitehead MA, Robinson D, O’Neill D, Langhorne P. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ. 2011;343:d6553.

15. Schäfer M, Körber MI, Vimalathasan R, Mauri V, Iliadis C, Ellis G, Whitehead MA, Robinson D, O’Neill D, Langhorne P. Risk stratification of patients undergoing percutaneous repair of mitral and tricuspid valves using a multidimensional geriatric assessment. Circ Cardiovasc Qual Outcomes. 2021;14:e007624.

16. Chetrit J, Mendis N, Afifalo J. Frailty: as simple as possible, but no simpler. Circ Cardiovasc Qual Outcomes. 2021;14:e008227.

17. Afifalo J, Lauck S, Kim DH, Lefèvre T, Piazza N, Lachapelle K, Martucci G, Lamy A, Labinaz M, Peterson MD, Arora RC, Noiseux N, Rassi A, Palacios IF, Généreux P, Lin dman BR, Asgar AW, Kim CA, Trnkus A, Maio RC, Ferrucci L. Multidimensional Prognostic Index based on frailty status in the systolic blood pressure intervention trial. J Hypertens. 2019;37:63–73.

18. Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2008;26:1147–55.

19. Basile G, Catalano A, Mondrafino G, Maltese G, Allibrandi A, Ciancio G, Lasco A, Cesari M. Relationship between blood pressure and frailty in older adults: A population-based study. J Clin Hypertens (Greenwich). 2019;21:1895–904.

20. Rockwood MR, Howlett SE. Blood pressure in relation to age and frailty. Can Geriatr J. 2011;14:2–7.

21. Basile G, Catalano A, Mondrafino G, Maltese G, Allibrandi A, Ciancio G, Lasco A, Cesari M. Relationship between blood pressure and frailty in older hypertensive outpatients. J Hypertens. 2018;36:53–61.

22. Ciancio G, Lasco A, Cesari M. Scanning electron microscopy examination of endothelium morphology in human carotid plaques. Micron. 2018;105:16–25.

23. Junius-Walker U, Onder G, Soleymani D, Wiese B, Albinina M, Lachapelle K, Piazza N, Martucci G, Bendayan M, Piankova P, Hayman V, Oumet MC, Rudski LG, Morin JP, Popma J, Webb JG, Perraü L. Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study. J Am Coll Cardiol. 2017;70:689–700.

24. Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019;74:594–607.

25. Marino F, Guasti L, Cosentino M, Rasini E, Ferrari M, Maio RC, Loraschi A, Cimpanelli MG, Schembri L, Legnaro M, Molteni E, Crespi C, Crema F, Venco A, Lecchi S. Simvastatin treatment in subjects at high cardiovascular risk modulates AT1R expression on circulating monocytes and T lymphocytes. J Hypertens. 2008;26:1147–55.

26. Congiu T, Schembri L, Tozzi M, Guasti L, Maio RC, Cosentino M, Marino F. Scanning electron microscopy examination of endothelium morphology in human carotid plaques. Micron. 2018;105:16–25.

27. Bhat N, Bhat X, Mohess DT, Bushan A, Tran H, Batchelor W, deFilippi CR, Walston JD, Bandeen-Roche K, Forman DE, Renger JS, Berkman FN, Gerstenblith G, Damluji AA. Interventions for frailty among older adults with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:482–503.

28. Rose AV, Duhamel T, Hyde C, Kent DE, Afifalo J, Schulz ASH, Chudky A, Renger JS, Dave M, Arora RC. Randomised controlled trial protocol for the PROTECT-CS Study: PROTein to Enhance outComes of (pre)frail paTients undergoing Cardiac Surgery. BMJ Open. 2021;11:e037240.

29. Vetrano DL, Palmer KM, Galluzzo L, Giampaoli S, Marengoni A, Bernabei R, Renger JS, Pfister G. Joint Action ADVANTAGE WP4 group. Hypertension and frailty: a systematic review and meta-analysis. BMJ Open. 2018;8:e024406.

30. Alapramian I, Sasaki E, Dos Santos MF, Izbicki R, Pulgrossi RC, Biella MM, Borge ACN, Sasaki MM, Torres LM, Fernández JS, Pião OA, Castro PLM, Fontenele PA, Yassuda MS. Hypertension and frailty in older adults. J Clin Hypertens (Greenwich). 2018;20:186–92.

31. Kang MG, Kim SW, Yoon SJ, Choi HY, Kim KI, Kim CH. Association between frailty and hypertension prevalence, treatment, and control in the elderly Korean Population. Sci Rep. 2017;7:7542.

32. Rockwood MR, Howlett SE. Blood pressure in relation to age and frailty. Can Geriatr J. 2011;14:2–7.

33. Basile G, Catalano A, Mondrafino G, Maltese G, Allibrandi A, Ciancio G, Lasco A, Cesari M. Relationship between blood pressure and frailty in older hypertensive outpatients. J Hypertens. 2018;37:63–73.

34. Sgolastra M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus AD, NICE, 2019. Hypertension in adults: diagnosis and management clinical guideline. BMJ. 2019;365:l1303.

35. Forman DE, Alexander KP. Frailty: a vital sign for older adults. Can J Cardiol. 2016;32:1082–7.

36. Blauth FG, Vilar LADS, Pontes VCB, Moriguti JC, Ferriolli E, Biella MM, Borges ACN, Sassaki MM, Torres LM, Klabunde W, deFilippi CR, Walston JD, Bandeen-Roche K, Forman DE, Resar JR, O’Connor CM, Gerstenblith G, Damluji AA. Interventions for frailty among older adults with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:482–503.
42. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/ABC/ACPM/AGS/APhA/ASH/ASC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71:2199–269.

43. Todd OM, Wilkinson C, Hale M, Wong NL, Sheppard JP, McManus RJ, Rockwood K, Young J, Gale CP, Clegg A. Is the association between blood pressure and mortality in older adults different with frailty? A systematic review and meta-analysis. Age Ageing. 2019;48:627–35.

44. Masoli JAH, Delgado J, Strain D, Melzer D. Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality. Age Ageing. 2020;49:807–13.

45. Streit S, Poortvliet RKE, Gussekloo J. Lower blood pressure during antihypertensive treatment is associated with higher all-cause mortality and accelerated cognitive decline in the oldest-old. Data from the Leiden 85-plus Study. Age Ageing. 2018;47:545–50.

46. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dimitrasucu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulbilt CJ, HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.

47. Ogliari G, Westendorp RG, Muller M, Mari D, Torresani E, Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Yoon SS, Burt V, Louis T, Carroll MD. Hypertension among the oldest-old. Data from the Leiden 85-plus Study. Age Ageing. 2019;48:627–35.

48. Odden MC, Peralta CA, Haan MN, Kovinsky KE. Rethinking the association between blood pressure and mortality in older and frail older patients. Circ Res. 2018;32:633–8.

49. Russo G, Liguori I, Aran L, Bulli G, Curfio F, Galizia G, Garigliol G, Testa G, Ungar A, Cacciarelli F, Bonaduce D, Abete P. Impact of SPRINT results on hypertension guidelines: implications for “frail” elderly patients. J Hum Hypertens. 2018;32:633–8.

50. Supiano MA, Williamson JD. Applying the systolic blood pressure intervention trial results to older adults. J Am Geriatr Soc. 2017;65:16–21.

51. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Halei WE, Hawthiel AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Laufer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shah BN, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JR, Pajewski NM, SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.

52. Hua Q, Fan L, Li J, Joint Committee for Guideline Revision. Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol. 2019;2019(16):67–99.

53. Mallory LH, Allen M, Fleming I, Kelly K, Bowles S, Duncan J, Moorhouse P. Promoting higher blood pressure targets for frail older adults: a consensus guideline from Canada. Cleve Clin J Med. 2014;81:427–37.

54. Chuang S-Y, Pan W-H, Chang H-Y, Wu C-I, Chen C-Y, Hsu CC. Protective Effect of calcium channel blockers against frailty in older adults with hypertension. J Am Geriatr Soc. 2016;64:1356–8.

55. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, Williamson JD, Marchionni N, Pahor M, Health, Aging and Body Composition Study. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Gerontol Soc. 2004;59(11):1356–8.

56. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, Carter C, Di Bari M, Guralnik JM, Pahor M. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359(9310):926–30.

57. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464–8.

58. Laing RE, Hess P, Shen Y, Wang J, Hu SX. The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr Drug Metab. 2011;12:460–86.

59. Luizon MR, Pereira DA, Sandrim VC. Pharmacogenomics of hypertension and preeclampsia: focus on gene-gene interactions. Front Pharmacol. 2018;9:168.

60. Padmanabhan S, Joe B. Towards precision medicine for hypertension: a review of genomic; epigenomic; and microbiomic effects on blood pressure in experimental rat models and humans. Physiol Rev. 2017;97:1469–528.
71. Rysz J, Franczyk B, Rysz-Górzyńska M, Gluba-Brzózka A. Pharmacogenomics of hypertension treatment. Int J Mol Sci. 2020;21:4709.

72. Torrellas C, Carril JC, Cacabelos R. Benefits of pharmacogenomics in the management of hypertension. J Pharmacogenomics Pharmacoproteomics. 2014;5:2.

73. Cacabelos R. The metabolomic paradigm of pharmacogenomics in complex disorders. Metabolomics. 2012;2:e119.

74. Just KS, Schneider KL, Schurig M, Stingl JC, Brockmöller J. The metabolomic paradigm of pharmacogenomics. Metabolomics. 2012;2:e119.

75. Gangavati A, Hajjar I, Quach L, Jones RN, Kiely DK, Gagnon P, Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker ST, Johnson JA, CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2:362–70.

76. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169:1952–60.

77. Arnott D, Davis BR, Ford CE, Boerwinkle E, Leideneker-Foster C, Miller MB, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GeneHAT) study. Circulation. 2005;111:3374–83.

78. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D, ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension. 2003;41:398–403.

79. Choi HD, Suh JH, Lee JY, Bae SK, Kang HE, Lee MG, Shin WG. Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: a meta-analysis. Int J Clin Pharmacol Ther. 2013;51:718–24.

80. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and anti-hypertensive response to a thiazide diuretic. Hypertension. 2001;37:739–43.

81. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langae TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshes AL, Boerwinkle E, Peplin CJ, Cooper-Dehoff RM, Johnson JA. Association of variants in NEDDML with blood pressure response and adverse cardiovascular outcomes in patients treated with thiazide diuretics. J Hypertens. 2013;31:698–704.

82. Hiltunen TP, Donner KM, Sarin AP, Saarela J, Ripatti S, Chapman AB, Gums JG, Gong Y, Cooper-Dehoff RM, Frau F, Glorioso V, Zaninello R, Salvi E, Glorioso N, Boerwinkle E, Turner ST, Johnson JA, Kontula KK. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015;4(1): e001521.

83. Frau F, Zaninello R, Salvi E, Ortu MF, Braga D, Velayutham D, Argiolas G, Fresa G, Troffa C, Bulla E. Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics. 2014;15:1643–52.

84. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012;59:1204–11.

85. Oliveira-Paula GH, Luizon MR, Lacchini R, Fontana V, Silva PS, Biagi C, Tanus-Santos JE. Gene–gene interactions among PRKCA; NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril. Basic Clin Pharmacol Toxicol. 2017;120:284–91.

86. Silva PS, Fontana V, Luizon MR, Lacchini R, Silva WA Jr, Biagi C, Tanus-Santos JE. eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol. 2013;69:167–77.

87. Beitelshes AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langae TY, Shriver MD, Sadee W, Knot DJ, Pepine CJ, Johnson JA, INVEST Investigators. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational Verapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007;17:79–29.

88. Beitelshes AL, Navare H, Wang D, Gong Y, Wessel J, Moss JJ, Langae TY, Cooper-Dehoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet. 2009;2:362–70.

89. Langae TY, Gong Y, Yarandi HN, Katz DA, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007;81:386–91.

90. Norris KC, Wright J. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlopidine among African American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31:95–103.

91. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlopidine in healthy Korean subjects. Clin Pharmacol Ther. 2006;80:646–56.

92. Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZL, Zhou HN, Pei Q, Guo CX, Wang IL, Yang GP, ABCB1 polymorphism and gender affect the pharmacokinetics of amlopidine in Chinese patients with essential hypertension: a population analysis. Drug Metab Pharmacokinet. 2014;29:305–11.

93. Agnoletti D, Valbusa F, Labat C, Gautier S, Mourad JJ, Benetos A. PARTAGE study investigators evidence for a prognostic role of orthostatic hypertension on survival in a very old institutionalized population. Hypertension. 2016;67:191–6.

94. Fedorowski A, Stavenov L, Hedblad B, Berglund G, Nilsson PM, Melander O. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmö Preventive Project). Eur Heart J. 2010;31:85–91.

95. Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Clin J Am Med. 2006;109:106–11.

96. Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, Curb JD. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation. 1998;98:2290–5.

97. Bogaerts JMK, van Bulmoos LM, Achterberg WP, Gussekloo J, Streit S, van der Ploeg MA, Drewes YM, Poortvliet RKE. Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases. Age Ageing. 2022;51:afab192.

98. Volgman AS, Nair G, Lyubarova R, Merchant FM, Mason P, Curtis AB, Wenger NK, Aggarwal NT, Kirkpatrick JN, Benefit HI. Management of atrial fibrillation in patients 75 years and older: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:166–79.

99. Proietti M, Marra AM, Tassone EJ, De Vuono S, Corrao S, Gobbi P, Perticone F, Corazza GR, Basili S, Lip GV, Visioli F, Raparelli V, ARAPACIS Study Investigators; GIS Group. Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. Am J Cardiol. 2014;37:870e874.

100. Wang S, Xue H, Zou Y, Sun K, Fu C, Wang H, Hui R. Left ventricular hypertrophy, abnormal ventricular geometry and relative wall thickness are associated with increased risk of stroke in hypertensive patients among the Han Chinese. Hypertens Res. 2014;37:870e874.
101. Barbesino G. Thyroid function changes in the elderly and their relationship to cardiovascular health: A Mini-Review. Gerontology. 2019;65:1–8.

102. Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, Kazakou P, Spartalis M, Spartalis E, Oikonomou E, Siasos G. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75:672–83.

103. Cooke CE, Xing S, Gale SE, Peters S. Initial non-adherence to antihypertensive medications in the United States: a systematic literature review. J Hum Hypertens. 2022;36:3–13.

104. Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F, Biganzoli EM, Nobili A, Mannucci PM, REPOSI Investigators. Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. Eur J Intern Med. 2015;26:330–7.

105. Richter D, Guasti L, Koehler F, Squizzato A, Nistri S, Christodorescu R, Die Hart F, Gaudio G, Asteggiano R, Ferrini M. Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice. ESC Heart Fail. 2021;8:3483–94.

106. Guasti L, Dilaveris P, Mamas MA, Richter D, Christodorescu R, Lumens J, Schuring MJ, Carugo S, Afifalo J, Ferrini M, Asteggiano R, Cowie MR. Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. Clinical Consensus Statement from the ESC Council for Cardiology Practice/Taskforce on Geriatric Cardiology, the ESC Digital Health Committee and the ESC Working Group on eCardiology. ESC Heart Fail. 2022. https://doi.org/10.1002/ehf2.14022.

107. https://www.ema.europa.eu/en/documents/scientific-guideline/position-paper-terminology-pharmacogenetics_en.pdf.